Compare Quest Diagnostics Inc (DGX) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs JPMorgan Diversified Return International Eqty ETF — how do they compare? Quest Diagnostics Inc trades at $205.87 (market cap $22.80B), while JPMorgan Diversified Return International Eqty ETF trades at $73.33. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while JPMorgan Diversified Return International Eqty ETF pays none. Which is the better fit depends on your goals.
| DGX | JPIN | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | — |
52-Week High | $216.02 | $76.96 |
52-Week Low | $166.42 | $63.14 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
JPIN trades at $72.785, down 0.78% on the day, with technical indicators showing a neutral to bearish bias. The stock faces resistance near $73 and support at $72. Recent corporate actions include a declared dividend of $0.91 scheduled for June 2026. Market sentiment remains mixed, with oscillators neutral and moving averages signaling bearish pressure.
The outlook for JPIN is cautious due to weak technical momentum and limited fundamental data availability. Key risks include market volatility and reliance on international equity performance. Investors should monitor upcoming financial disclosures for clarity on valuation and profitability metrics to assess long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
